All Phenotypes Tg(Ins1-cre/ERT)1Lphi MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Ier3ip1^tm1Arvn/Ier3ip1^tm1Arvn Tg(Ins1-cre/ERT)1Lphi/0	involves: 129S4/SvJaeSor * C57BL/6J * CD-1	MGI:7620431
cn2	Gck^tm1Ydor/Gck⁺ Tg(Ins1-cre/ERT)1Lphi/0	involves: C57BL/6 * C57BL/6J * CD-1	MGI:6690684
cn3	Abhd6^{tm1c(EUCOMM)Hmgu}/Abhd6^{tm1c(EUCOMM)Hmgu} Tg(Ins1-cre/ERT)1Lphi/0	involves: C57BL/6N * CD-1	MGI:6276028

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

homeostasis/metabolism

abnormal glucose homeostasis ( J:336782 )

• male mice treated with tamoxifen at 8 weeks of age (to induce IER3IP1 deletion in beta cells in early adulthood) develop a diabetic phenotype

decreased insulin secretion ( J:336782 )

• adult male mice show a reduction of proinsulin and insulin content in pancreatic islets at 2 and 4 weeks after tamoxifen injection

hyperglycemia ( J:336782 )

• adult mice show persistent hyperglycemia at 4 weeks after tamoxifen injection

decreased circulating insulin level ( J:336782 )

• adult mice show decreased serum insulin levels at 4 weeks after tamoxifen injection

impaired glucose tolerance ( J:336782 )

• adult mice show significantly higher blood glucose levels than control littermates at all time points tested in oral glucose tolerance tests starting from 2 weeks after tamoxifen injection

endocrine/exocrine glands

increased pancreatic beta cell apoptosis ( J:336782 )

• pancreatic islets show significantly increased mRNA levels of Trib3 (a mediator of ER stress-induced cell death) at 4 weeks after tamoxifen injection

• in contrast, mRNA levels of the antiapoptotic gene Bcl2 are significantly suppressed

decreased pancreatic beta cell proliferation ( J:336782 )

• pancreatic islets show significantly increased mRNA levels of the cell growth inhibitor p21/Cdkn1a at 4 weeks after tamoxifen injection

abnormal pancreatic beta cell morphology ( J:336782 )

• adult male mice show a more-diffuse cytoplasmic distribution of proinsulin and increased Pro+/Ins-cells at 4 weeks after tamoxifen injection

abnormal pancreatic beta cell differentiation ( J:336782 )

• pancreatic islets of adult male mice show significantly reduced mRNA levels of beta-cell transcription factors both at 2 weeks (Mafa) and at 4 weeks (Mafa, Pdx1, and Nkx6-1) after tamoxifen injection, along with decreases in PDX1 and NKX6-1 protein levels at 4 weeks post-injection

decreased insulin secretion ( J:336782 )

• adult male mice show a reduction of proinsulin and insulin content in pancreatic islets at 2 and 4 weeks after tamoxifen injection

cellular

increased pancreatic beta cell apoptosis ( J:336782 )

• pancreatic islets show significantly increased mRNA levels of Trib3 (a mediator of ER stress-induced cell death) at 4 weeks after tamoxifen injection

• in contrast, mRNA levels of the antiapoptotic gene Bcl2 are significantly suppressed

abnormal pancreatic beta cell differentiation ( J:336782 )

decreased pancreatic beta cell proliferation ( J:336782 )

• pancreatic islets show significantly increased mRNA levels of the cell growth inhibitor p21/Cdkn1a at 4 weeks after tamoxifen injection

Allelic Composition	Gck^tm1Ydor/Gck⁺ Tg(Ins1-cre/ERT)1Lphi/0
Genetic Background	involves: C57BL/6 * C57BL/6J * CD-1

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gck^tm1Ydor mutation (0 available); any Gck mutation (59 available)
Tg(Ins1-cre/ERT)1Lphi mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

homeostasis/metabolism

hypoglycemia ( J:302600 )

• mice treated with tamoxifen exhibit long-term, persistent hypoglycemia

impaired glucose tolerance ( J:302600 )

• 9-month-old tamoxifen-treated mice, but not 1.5-month-old tamoxifen-treated mice, exhibit abnormal glucose tolerance

endocrine/exocrine glands

increased pancreatic beta cell mass ( J:302600 )

• tamoxifen-treated mice exhibit an increase in beta cell mass at 1.5 months of age, but this increase is no longer seen at 9 months of age

Allelic Composition	Abhd6^{tm1c(EUCOMM)Hmgu}/Abhd6^{tm1c(EUCOMM)Hmgu} Tg(Ins1-cre/ERT)1Lphi/0
Genetic Background	involves: C57BL/6N * CD-1
Cell Lines	HEPD0651_8_C07

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Abhd6^{tm1c(EUCOMM)Hmgu} mutation (0 available); any Abhd6 mutation (35 available)
Tg(Ins1-cre/ERT)1Lphi mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

endocrine/exocrine glands

increased insulin secretion ( J:215257 )

• islets from tamoxifen-treated mice show enhanced glucose-stimulated insulin secretion

• however, tamoxifen treated mice show normal body weight, food intake and no changes in beta cell mass

homeostasis/metabolism

increased insulin secretion ( J:215257 )

• islets from tamoxifen-treated mice show enhanced glucose-stimulated insulin secretion

• however, tamoxifen treated mice show normal body weight, food intake and no changes in beta cell mass

increased circulating insulin level ( J:215257 )

• tamoxifen-treated males show elevated insulinemia during oral glucose tolerance test

improved glucose tolerance ( J:215257 )

• tamoxifen-treated males show slightly improved glucose tolerance during oral glucose tolerance test

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/16/2024 MGI 6.23